Pharmacountry lists 95 active suppliers of Semaglutide.
The largest concentration is in China, which accounts for 51 suppliers (over half of the total). Buyers should consider potential lead‑time variability and may want to qualify multiple Chinese manufacturers to mitigate supply risk.
India follows with 19 suppliers, offering a secondary hub in Asia. Sourcing from India can provide competitive pricing and serve as a diversification point if Chinese supply is constrained.
The United States contributes 5 suppliers, representing a smaller but strategically important source for buyers seeking domestic or FDA‑aligned manufacturing.
Switzerland adds 2 high‑tech suppliers, while the Republic of Korea, Taiwan, the Netherlands, and France each have a single supplier, offering niche options for specialized requirements.
Overall, diversifying across these regions can improve supply security, balance lead times, and align with regulatory preferences.
留下您的评分